☆ 4.3 Article

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients

HEMASPHERE (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

TET2 guards against unchecked BATF3-induced CAR T cell expansion

Nayan Jain et al.

Summary: Further advancements in cell engineering are necessary to improve the effectiveness of CAR and other T cell-based therapies. Disrupting TET2 can enhance T cell-mediated tumor rejection, but it also carries the risk of clonal expansions and tissue infiltration by CAR T cells.

NATURE (2023)

Add to Collection

Article Hematology

Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke

Christopher M. Arends et al.

Summary: Clonal hematopoiesis (CH) is common among older people and is associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. This study investigated CH in patients with first-ever ischemic stroke and found that CH is associated with an increased risk of recurrent vascular events and death.

BLOOD (2023)

Add to Collection

Article Hematology

Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial

Christopher Maximilian Arends et al.

BLOOD (2022)

Add to Collection

Article Oncology

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9

Friederike Christen et al.

Summary: By using CRISPR/Cas9 technology to introduce mutations in healthy, young hematopoietic progenitor cells from umbilical cord blood samples, this study investigated the impact of clonal hematopoiesis-associated gene mutations on human stem and progenitor cells. The results showed enhanced self-renewal capacities in TET2 mutated cells and a mutation-specific impact on clonal composition of HSPCs after long-term culture experiments. This study provides evidence for the direct impact of clonal hematopoiesis-associated mutations on self-renewal and clonal composition of human stem and progenitor cells without confounding factors like age or a complex mutational landscape.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment

Raphael Teipel et al.

Summary: Inflammation plays a crucial role in CAR T-cell therapy, and clonal hematopoiesis of indetermined potential (CHIP) is commonly observed in this treatment setting. This study found that 34% of patients had CHIP before and after CAR T-cell treatment. However, patients with CHIP had a comparable response rate and improved overall survival.

BLOOD ADVANCES (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Add to Collection

Article Oncology

Compartment-specific mutational landscape of clonal hematopoiesis

Luise Hartmann et al.

Summary: This study investigated CH driver mutations in healthy individuals and found that variant allele frequencies were higher in BM compared to PB, positively correlated with the number of driver variants, and remained stable during follow-up. Spatial heterogeneity was detected in CH carriers, with different ASXL1 mutations showing distinct lineage distribution patterns. Patients with myeloid malignancies had higher mutation numbers and allele frequencies.

LEUKEMIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy et al.

Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma (Publication with Expression of Concern. See vol. 4, pg. 246, 2023)

Neeraj Y. Saini et al.

Summary: This study reveals that clonal hematopoiesis mutations, particularly those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Furthermore, the incidence of therapy-related myeloid neoplasms after CAR T-cell therapy is higher in clonal hematopoiesis-positive patients.

BLOOD CANCER DISCOVERY (2022)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling

Daniel Hormaechea-Agulla et al.

Summary: The study demonstrates that IFN gamma signaling induced during chronic infection can drive DNMT3A-loss-of-function clonal hematopoiesis. This suggests that environmental factors play an important role in the development of CH.

CELL STEM CELL (2021)

Add to Collection

Article Hematology

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

Michael Heuser et al.

Summary: Non-DTA mutations serve as prognostic NGS-MRD markers post-alloHCT in patients with acute myeloid leukemia, while MRD positivity is an independent adverse predictor of relapse, relapse-free survival, and overall survival.

BLOOD ADVANCES (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

The vicious and virtuous circles of clonal hematopoiesis

Nili Furer et al.

NATURE MEDICINE (2021)

Add to Collection

Article Hematology

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Peter G. Miller et al.

Summary: CHIP, a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is common in patients receiving CAR T-cell therapy but does not impact progression-free or overall survival, especially in patients younger than 60 years old. Although it can influence response rates and cytokine release syndrome severity, it should not be a factor in determining eligibility for this potentially life-prolonging treatment.

BLOOD ADVANCES (2021)

Add to Collection

Letter Hematology

Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Christopher Maximilian Arends et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Genetics & Heredity

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Kelly L. Bolton et al.

NATURE GENETICS (2020)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Oncology

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation

Mareike Frick et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome

Soichi Sano et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Oncology

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis

Christopher Maximilian Arends et al.

LEUKEMIA (2018)

Add to Collection

Article Multidisciplinary Sciences

Prediction of acute myeloid leukaemia risk in healthy individuals

Sagi Abelson et al.

NATURE (2018)

Add to Collection

Article Multidisciplinary Sciences

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Joseph A. Fraietta et al.

NATURE (2018)

Add to Collection

Article Oncology

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

Christopher J. Gibson et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

S. Jaiswal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

Jose J. Fuster et al.

SCIENCE (2017)

Add to Collection

Article Hematology

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump et al.

BLOOD (2017)

Add to Collection

Article Cell & Tissue Engineering

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

Catherine C. Coombs et al.

CELL STEM CELL (2017)

Add to Collection

Article Hematology

DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions

Manuel Buscarlet et al.

BLOOD (2017)

Add to Collection

Article Genetics & Heredity

Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life

Rocio Acuna-Hidalgo et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2017)

Add to Collection

Article Medicine, General & Internal

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

Siddhartha Jaiswal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.